Buy REMICADE® 100mg vial (Non-English) Online

Product Description

REMICADE is a prescription medicine that is approved for patients with:
• Rheumatoid Arthritis – adults with moderately to severely active rheumatoid arthritis, along with the medicine methotrexate.
• Crohn’s Disease – children 6 years and older and adults with Crohn’s disease who have not responded well to other medicines.
• Ankylosing Spondylitis in adults
• Psoriatic Arthritis in adults
• Plaque Psoriasis – adult patients with plaque psoriasis that is chronic (does not go away), severe, extensive, and/or disabling.
• Ulcerative Colitis – children 6 years and older and adults with moderately to severely active ulcerative colitis who have not
responded well to other medicines.
REMICADE blocks the action of a protein in your body called tumor necrosis factor-alpha (TNF-alpha). TNF-alpha is made by your
body’s immune system. People with certain diseases have too much TNF-alpha that can cause the immune system to attack normal
healthy parts of the body. REMICADE can block the damage caused by too much TNF-alpha.

What is Remicade?

Remicade is a prescription only medicine that is made of infliximab, which is a potent Tumor Necrosis Factor (TNF-alpha or TNF-α) blocker. This chimeric monoclonal antibody is manufactured using recombinant technology by continuous perfusion. The resulting medicine the appears as freeze-dried white pellet powder that is supplied in a vial made of type 1 glass and sealed with a rubber stopper and aluminum seal. Each glass vial contains 100mg of infliximab that must be reconstituted with 10ml of water for injection to produce an opalescent and colorless to light yellow solution with a concentration of 10mg of infliximab in each ml. The reconstituted solution must be diluted with appropriate amount of sodium chloride 9 mg/ml (0.9%) solution until the final solution has a volume of 250ml. This final solution should administered via an intravenous (IV) infusion.

What is Remicade used for?

Remicade is indicated for the treatment of rheumatoid arthritis (RA) in conjunction with the use of methotrexate. It is also indicated for the treatment of Crohn’s disease and ulcerative colitis in patients who have not responded adequately to the respective conventional therapy for these conditions. Remicade can treat these conditions in pediatric patients that are aged six to 17 years old. Remicade can also treat ankylosing spondylitis, psoriatic arthritis ,and plaque psoriasis in adult patients.

Why use Remicade?

The active ingredient in Remicade, infliximab, binds with high affinity to both transmembrane and soluble forms of TNF-alpha. This results in the interruption of pro-inflammatory processes in the body and the reduced synthesis of inflammatory cytokines. A patient’s inflammatory disorder will then be effectively regulated.